Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21260838 | 0.93 | ESR1 (0.50) | ESR1ESR2 | |
| SCHEMBL21260892 | 0.91 | ESR1 (0.47) | ESR1ESR2HSD17B1 | |
| SCHEMBL21260884 | 0.90 | ESR1 (0.46) | ESR1ESR2HSD17B1 | |
| SCHEMBL21260777 | 0.89 | ESR1 (0.49) | ESR1HSD17B1 | |
| SCHEMBL21261040 | 0.89 | ESR1 (0.44) | ESR1UCHL1ESR2 | |
| SCHEMBL21260985 | 0.88 | ESR1 (0.55) | ESR1 | |
| SCHEMBL21260833 | 0.88 | ESR1 (0.52) | ESR1 | |
| SCHEMBL21261067 | 0.88 | ESR1 (0.46) | ESR1ESR2 | |
| SCHEMBL21260770 | 0.88 | ESR1 (0.45) | ESR1UCHL1ESR2HSD17B1 | |
| SCHEMBL21260836 | 0.88 | ESR1 (0.48) | ESR1ESR2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703747-B2 | Benzothiophene-based selective mixed estrogen receptor downregulators | The Board of Directors of the University of Illinois (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190248780-A1 | BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLNOIS (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248780-A1 | BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS | ESR1, ESR2, GPER1 | ESR1 1/4885UCHL1 4143/4885ESR2 2/4885 |
| US-10703747-B2 | Benzothiophene-based selective mixed estrogen receptor downregulators | ESR1, ESR2, GPER1 | ESR1 1/4885UCHL1 4143/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.